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Adiponectin is an adipocyte-specific cytokine that has a
protective role in the development of cardiovascular
morbidities. As chronic kidney disease progresses,
adiponectin levels increase and cardiovascular risk profiles
change. Here we determined the association of baseline and
longitudinal changes in adiponectin with different
cardiovascular outcomes in 1255 type 2 diabetic
hemodialysis patients in the German Diabetes and Dialysis
Study. Within 4 years of follow-up, the hazard ratios to reach
pre-specified, adjudicated end points were determined. The
increased risk of cardiovascular events observed with high
adiponectin levels at baseline was associated with high risks
of sudden death and stroke but not of myocardial infarction.
Adiponectin was negatively correlated with C-reactive
protein and positively correlated with NT-pro-BNP, the latter
significantly attenuating the associations with adverse
outcome. Increased longitudinal levels of adiponectin during
follow-up were associated with higher risks of adverse
cardiovascular outcomes and death; associations weakened
by a confounding effect of increased NT-pro-BNP. Our study
suggests that high basal and increasing adiponectin levels in
the dialysis population largely reflect a consequence of
disease circumstances. Most likely, this rise is a counter-
regulatory response to worsening health in keeping with
adiponectin’s potential to counteract inflammation.
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Adiponectin is an adipocyte-specific cytokine that is inversely
correlated with body mass index (BMI),1,2 and has been
suggested to have a protective role in the development of
cardiovascular (CV) comorbidities. Adiponectin has been
found to improve hepatic3 and muscular insulin sensitivity,4
to ameliorate endothelial function,5 and to counteract
inflammation.5–7 In the general population, high levels of
adiponectin were found to be associated with less CV
complications, such as coronary artery disease8,9 and
myocardial infarction (MI).10
Serum levels of adiponectin are increased more than
twofold in renal failure.11 Similar observations of high
adiponectin being linked with a better CV outcome have
been reported,11,12 but some studies showed contrary results:
a high adiponectin level was found to be associated with a
high CV mortality13 and a progressive decline of renal
function.14
In advanced chronic kidney disease and end-stage renal
disease, the pattern and composition of risk is changing. CV
risk is determined by various components such as sudden
death (SD), stroke, and MI, and may vary because of
changing proportions of the components. By now, the
association of baseline adiponectin with SD, stroke, and MI
is unclear in renal patients, and associations of longitudinal
changes of adiponectin with these outcomes have not been
investigated so far. Furthermore, uncertainty exists about
pathways that underlie the associations of adiponectin with
adverse outcomes in patients with renal failure.
The aim of this study was threefold: first to assess the
association of baseline adiponectin with SD, stroke, MI,
combined CV events (CVEs), and all-cause mortality in
dialysis patients, second to assess the association of long-
itudinal changes of adiponectin with these outcomes,
and third to investigate the role of potential new factors in
the association of adiponectin with outcome. To this end,
data from the German Diabetes Dialysis Study (4D study
(Die Deutsche Diabetes Dialyse Studie)), which evaluated
atorvastatin in 1255 patients with type 2 diabetes mellitus on
maintenance hemodialysis treatment,15 were analyzed.
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RESULTS
Patient characteristics
Between March 1998 and October 2002, a total of 1255
patients were included into the 4D study. Of these, 1249
patients had a baseline and 1205 had a post-baseline
adiponectin measurement after a median of 182 days
(interquartile range 177–185 days), with 1202 patients having
both. The mean follow-up period was 3.96 years (median 4.0
years) on atorvastatin and 3.91 years (median 4.08 years) on
placebo. During follow-up, 617 patients died (160 of SD).
Furthermore, 469 patients reached the composite CV end
point (CVE: cardiac death, stroke, and MI), with stroke and
MI occurring in 99 and 200 patients, respectively.
In the study population (n¼ 1249), the mean age was
65.7±8.3 years, and 54% of the patients were male. The
median baseline adiponectin level was 13.8mg/l (interquar-
tile range 10–20); the median post-baseline adiponectin level
(after 6 months of follow-up) was 13.7mg/l (10.0–20.3), with
no significant differences being present between the atorvas-
tatin and the placebo group. The baseline patient character-
istics are shown in Table 1.
Baseline adiponectin and outcome
Baseline adiponectin (continuous variable) was, in crude
analyses, significantly associated with the risks of stroke, SD,
and CVE. Per unit increase in log-transformed adiponectin,
the risk of stroke increased by 66%, SD by 40%, and CVE by
26% (Table 2). When patients were divided into categories
according to their adiponectin level at baseline, those in the
highest adiponectin quartile had a 42-fold higher risk of
stroke (hazard ratio (HR) (95% confidence interval) 2.39
(1.28–4.48)), a 51% higher risk of SD (1.51 (0.99–2.31)), and
a 33% higher risk of experiencing a CVE (1.33 (1.03–1.72)),
as compared with patients in the lowest quartile (Table 3).
For building our multivariate models, we distinguished
between confounding and intermediate conditions as known
from the literature (the latter being part of a causal pathway).
We especially evaluated further potentially important
factors: BMI, N-terminal pro-B-type natriuretic peptide (NT-
pro-BNP), and C-reactive protein (CRP). Adiponectin was
inversely correlated to BMI (r¼0.20, Po0.001; Figure 1a)
and positively to NT-pro-BNP (r¼ 0.28, Po0.001; Figure
1b), both identified as confounders. As experimental data
showed that adiponectin suppresses inflammation and CRP
(negative correlation r¼0.27, Po0.001; Figure 1c), the
latter constitutes an intermediate condition, adjustments for
which would not be warranted in epidemiological analyses. If
performed, the resulting effect estimates would represent the
association of adiponectin with outcome, excluding the
mechanism by its beneficial action on inflammation.
Subsequently, multivariate analyses were performed with a
stepwise inclusion of confounders. Adjustments for age,
gender, atorvastatin treatment, coronary heart disease,
congestive heart failure, duration of type 2 diabetes mellitus,
smoking status, and blood pressure did not meaningfully
change the association of adiponectin with adverse outcomes
except for stroke (Table 2). Although further inclusion of
BMI hardly changed the effect estimates, interestingly,
NT-pro-BNP strongly impacted and attenuated the associa-
tions of adiponectin with outcomes (final models; Table 2).
Results from the categorical analyses including all the above-
mentioned confounders are shown in Table 3.
To strengthen the assumption of CRP being an inter-
mediate condition, we performed explorative analyses. When
the final multivariate models, described above, were addi-
tionally adjusted for CRP, that is when the suggested
mechanism of adiponectin to improve inflammation was
excluded, the risks expectedly became significantly higher:
hazard ratios for log adiponectin to reach CVE increased
from 1.03 to 1.11, SD from 1.12 to 1.22, stroke from 1.14 to
1.22, MI from 0.86 to 0.90, and all-cause mortality from 0.88
to 1.03, respectively. Further adjustments for triglycerides and
high-density lipoprotein cholesterol, which may also repre-
sent intermediate conditions, did not materially change
the results.
Additional analyses on adiponectin and adverse outcomes
in subgroups of patients free of CV disease at baseline yielded
similar results, as did stratified analyses by male and female
gender. To study the potential impact of informative
censoring by deaths, we did further investigations using
combined end points of death and MI, and death and stroke.
Similarly to our primary analyses, no association of
adiponectin with MI was found, whereas an increase in
stroke was noted in crude analyses (data not shown).
Change from baseline adiponectin and outcome
For our longitudinal analyses, we assessed the percentage
change of adiponectin from baseline to the next available
follow-up measurement (change in adiponectin¼ ratio
adiponectinf-up/adiponectinbaseline). Correlation analyses
showed that the change in adiponectin was strongly
correlated to the change in NT-pro-BNP (r¼ 0.23,
Po0.001) and inversely to the change in BMI (r¼0.12,
Po0.001). Furthermore, a rise in adiponectin was strongly
correlated to a decrease in CRP (r¼0.16, Po0.001).
In Cox regression analyses on the association of changes in
adiponectin with outcome, the crude relative risk of SD, MI,
CVE, and all-cause mortality increased considerably per
unit increase in the log-transformed adiponectin change
(continuous variable). When patients were divided into
tertiles according to the percent change in adiponectin
(patient characteristics are shown in Table 4), those with
greater than 12.3% increasing adiponectin levels (third
tertile) had in crude analyses a significant 51% higher risk
of SD, a 66% higher risk of MI, a 33% higher risk of CVE,
and a 29% higher risk of all-cause death, compared with
patients with decreasing adiponectin levels in the first tertile
(reference group) (Figure 2a–c and Table 5). After multi-
variate adjustments for baseline variables and the long-
itudinal changes in BMI and NT-pro-BNP, the association of
increasing adiponectin with adverse outcomes attenuated
largely. Again, NT-pro-BNP had a significant impact, with
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adjustments for its longitudinal change meaningfully contri-
buting to attenuate the risks. The HRs and 95% confidence
intervals from both crude and adjusted analyses of adiponectin
changes on all outcomes are shown in Table 5. Additional
adjustments for triglycerides and high-density lipoprotein
cholesterol levels did not materially change the results.
Taking informative censoring by death into account,
analyses of MI and stroke showed that rising adiponectin
over 6 months (log-transformed ratio adiponectinf-up/
adiponectinbaseline) increased the crude risks of the combined
end points of MI and death and stroke and death
significantly (HRMIþ death 1.45 (1.17–1.78), HRstrokeþ death
1.39 (1.09–1.64)), and were attenuated after multivariate
adjustments.
DISCUSSION
This study investigated the association of two consecutive
adiponectin measurements with SD, stroke, and MI as—
pathophysiologically different—components of CVEs, and
all-cause mortality. The main findings within a large cohort
Table 1 | Patient characteristics according to quartiles of adiponectin at baseline; study population n=1249
Adiponectin (mg/l)
Characteristic p9.97 (n=314) 49.97 to p13.80 (n=311) 413.80 to p19.85 (n=314) 419.85 (n=310)
Age (years) 65 (9) 66 (8) 66 (8) 66 (8)
Gender (% male) 61 51 53 51
BMI (kg/m2) 28.2 (4.7) 28.3 (4.9) 27.9 (4.9) 25.8 (4.3)
Atorvastatin treatment (%) 51 51 51 50
Smoker/ex-smoker (%) 46 37 37 42
Systolic BP (mmHg) 144 (22) 145 (23) 147 (23) 147 (20)
Diastolic BP (mmHg) 74 (10) 75 (12) 77 (11) 77 (11)
HbA1c (%) 6.8 (1.3) 6.7 (1.2) 6.6 (1.3) 6.7 (1.3)
Duration of diabetes (years) 16.7 (9.0) 18.7 (8.8) 18.0 (8.9) 18.9 (8.3)
Time on dialysis (months) 8 (6) 8 (7) 9 (8) 8 (7)
History of
CAD (%) 34 29 22 32
CHF (%) 41 35 31 35
Lipid values (mg per 100ml)
Total cholesterol 221 (42) 221 (42) 219 (43) 216 (43)
LDL cholesterol 122 (30) 125 (28) 128 (31) 127 (30)
HDL cholesterol 31 (11) 33 (10) 37 (11) 44 (16)
Triglycerides 284 (189; 414) 242 (171; 360) 213 (143; 293) 157 (116; 245)
Adiponectin (mg/l) 7.9 (1.5) 11.8 (1.1) 16.3 (1.7) 29.2 (11.0)
C-reactive protein (mg/l) 7.7 (3.3; 17.6) 5.5 (2.8; 13.4) 4.7 (2.1; 12.0) 3.3 (1.5; 7.5)
Albumin (g per 100ml) 3.8 (0.3) 3.8 (0.3) 3.8 (0.3) 3.8 (0.3)
Hemoglobin (g per 100ml) 10.9 (1.4) 10.8 (1.3) 10.9 (1.4) 11.1 (1.4)
NT-pro-BNP (pg/ml) 2075 (948; 5604) 3426 (1338; 7346) 3212 (1487; 9262) 5689 (2351; 16694)
BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide.
Values are presented as means (s.d.) or median (interquartile range) or %.
Table 2 | Baseline adiponectin (continuous variable, log transformed) and the risk of sudden death, stroke, myocardial
infarction, combined cardiovascular events, and all-cause mortality; study population n=1249
HR and 95% CI
Outcome Crude Adjusteda Adjusteda+BMI Adjusteda+BMI, NT-pro-BNP
Combined cardiovascular events 1.26 (1.05–1.51) 1.27 (1.05–1.52) 1.23 (1.02–1.48) 1.03 (0.85–1.25)
P=0.013 P=0.011 P=0.028 P=0.731
Sudden death 1.40 (1.02–1.90) 1.39 (1.02–1.89) 1.31 (0.96–1.79) 1.12 (0.81–1.54)
P=0.036 P=0.037 P=0.093 P=0.511
Stroke 1.66 (1.12–2.45) 1.44 (0.97–2.14) 1.45 (0.97–2.18) 1.14 (0.75–1.73)
P=0.011 P=0.074 P=0.071 P=0.555
Myocardial infarction 0.91 (0.68–1.20) 0.94 (0.71–1.25) 0.96 (0.72–1.28) 0.86 (0.64–1.16)
P=0.487 P=0.671 P=0.789 P=0.321
All-cause death 1.10 (0.94–1.30) 1.10 (0.94–1.30) 1.06 (0.90–1.25) 0.88 (0.74–1.04)
P=0.239 P=0.233 P=0.474 P=0.129
BMI, body mass index; CI, confidence interval; HR, hazard ratio; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide.
aAnalyses were adjusted for age, gender, atorvastatin treatment, coronary artery disease, congestive heart failure, duration of type 2 diabetes mellitus, smoking status, and
systolic blood pressure.
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of diabetic hemodialysis patients were that a high adipo-
nectin level at baseline was associated with an increased risk
of CVE, mainly due to the high risks of SD and stroke, but
not of MI. Increasing adiponectin during follow-up was
associated with increased risks of adverse outcomes. NT-pro-
BNP and its longitudinal change turned out to be a strong
confounder and meaningfully attenuated the associations of
adiponectin with adverse outcomes. In addition, high levels
of adiponectin were correlated with low levels of CRP, the
latter potentially being an effect of adiponectin.
Table 3 | Risk (HR and 95% CI) of sudden death, stroke, myocardial infarction, combined cardiovascular events, and all-cause
mortality by quartiles of adiponectin at baseline; study population n=1249
Adiponectin level at baseline (mg/l)
Outcome p9.97 (n=314) 49.97 to p13.80 (n=311) 413.80 to p19.85 (n=314) 419.85 (n=310)
Cardiovascular events
Crude HR (95% CI) 1 1.23 (0.94–1.60) 1.01 (0.77–1.31) 1.33 (1.03–1.72)
Adjusteda HR (95% CI) 1 1.17 (0.88–1.55) 1.06 (0.79–1.40) 1.06 (0.80–1.40)
Sudden death
Crude HR (95% CI) 1 1.18 (0.75–1.84) 0.77 (0.47–1.25) 1.51 (0.99–2.31)
Adjusteda HR (95% CI) 1 1.05 (0.66–1.68) 0.72 (0.43–1.21) 0.99 (0.62–1.57)
Stroke
Crude HR (95% CI) 1 1.87 (0.97–3.60) 1.92 (1.01–3.64) 2.39 (1.28–4.48)
Adjusteda HR (95% CI) 1 1.78 (0.86–3.65) 1.65 (0.80–3.39) 1.72 (0.84–3.52)
Myocardial infarction
Crude HR (95% CI) 1 1.01 (0.69–1.48) 0.91 (0.62–1.33) 0.81 (0.54–1.20)
Adjusteda HR (95% CI) 1 0.99 (0.65–1.49) 1.08 (0.72–1.61) 0.80 (0.52–1.23)
All-cause death
Crude HR (95% CI) 1 1.13 (0.90–1.41) 0.91 (0.73–1.15) 1.14 (0.91–1.42)
Adjusteda HR (95% CI) 1 1.03 (0.81–1.31) 0.90 (0.70–1.15) 0.80 (0.62–1.02)
CI, confidence interval; HR, hazard ratio.
aAnalyses were adjusted for age, gender, atorvastatin treatment, coronary artery disease, congestive heart failure, duration of type 2 diabetes mellitus, smoking status, systolic
blood pressure, body mass index, and N-terminal pro-B-type natriuretic peptide.
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Figure 1 |Correlations of adiponectin with BMI NT-Pro BNP and CRP. (a–c) Correlations of adiponectin (log transformed) with (a) body
mass index, (b) NT-pro-BNP (log transformed), and (c) C-reactive protein (log transformed).
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Mean adiponectin serum concentration in the general
population is approximately 6mg/l.16 Low levels of adipo-
nectin were associated with coronary artery disease in men9
and increased the risk of MI.10 Similarly, investigations in
hemodialysis patients and in patients with chronic kidney
disease found low adiponectin levels to be associated with
poor CVoutcome.11,12,17 In contrast, recent studies suggested
a high rather than a low adiponectin level to be associated
with increased CV and all-cause mortality, and with a higher
decline of renal function.13,14,18 One possible reason for the
discrepant results may lie in varying proportions of the—
pathophysiologically different—components of CV outcome.
The pattern of risk is changing in chronic kidney disease and
end-stage renal disease, compared with that in healthy
subjects. Whereas people from the general population mainly
die from MI, SD represents the most prominent event in
dialysis patients, accounting for 25% of all-cause mortality.19
Therefore, our study adds important new knowledge,
investigating the individual components of CV outcome
and showing that the association of a high baseline
adiponectin with CVE was indeed mainly explained by the
risks of SD and stroke, and not of MI.
One further reason for the differing results in literature
may be sought in the complex mechanisms by which
adiponectin is regulated. The differentiation of causes from
consequences, actions from reactions, and true effects from
confounding is essential. In this context, our study provides
important information, distinguishing confounding from
intermediate conditions. It also especially investigates poten-
tial new factors with their impact in the association of
adiponectin with outcome by applying a stepwise approach:
adjusting the crude models for a variety of confounders as
being known from the literature did not meaningfully change
the effect estimates derived for the association of adiponectin
with adverse outcomes. Thereafter, we attempted to investi-
gate poor nutritional status and wasting, as partly being
reflected by a low BMI. Wasting is known to affect
adiponectin levels13,20 and is associated with a poor out-
come.21,22 Experimental data suggest that adiponectin may be
associated with weight loss secondary to increased energy
expenditure.23,24 Conversely, one study showed that weight
loss increased plasma adiponectin levels.25 In fact, additional
adjustment of the analyses for BMI did either not or only
slightly diminish the risks. This suggests that apart from the
complexity of poor nutritional status, which may hardly be
possible to adequately adjust for, other pathologic processes
may also contribute and underlie the observed associations of
high adiponectin with poor outcome.
In this context, it is of particular interest that NT-pro-BNP
appears to play a crucial role in adiponectin metabolism.
Table 4 | Patient characteristics according to tertiles of the percentage change in adiponectin from baseline; study population
n=1202
Percentage change in adiponectin from baseline
Characteristic Decrease p–12.8% (n=400) Stable 12.8 to +12.3% (n=402) Increase 412.3% (n=400)
Age (years) 65 (8) 66 (8) 66 (8)
Gender (% male) 56 53 52
BMI (kg/m2) 28.0 (5.1) 28.0 (4.9) 26.8 (4.5)
Atorvastatin treatment (%) 52 48 49
Smoker/ex-smoker (%) 39 39 42
Systolic BP (mmHg) 145 (22) 146 (22) 146 (22)
Diastolic BP (mmHg) 75 (11) 77 (11) 75 (11)
HbA1c (%) 6.8 (1.4) 6.8 (1.2) 6.6 (1.1)
Duration of diabetes (years) 18.4 (8.5) 18.6 (8.9) 17.3 (8.8)
Time on dialysis (months) 8 (7) 9 (7) 8 (7)
History of
CAD (%) 31 29 28
CHF (%) 31 35 39
Lipid values (mg per 100ml)
Total cholesterol 223 (42) 217 (41) 218 (43)
LDL cholesterol 128 (30) 124 (30) 126 (29)
HDL cholesterol 38 (14) 35 (14) 36 (12)
Triglycerides 226 (150; 313) 224 (150; 353) 216 (149; 311)
Adiponectin changea (mg/l) 4.4 (7.8; 2.6) 0.1 (0.9; 0.7) 4.6 (2.4; 8.8)
C-reactive protein (mg/l) 4.3 (1.9; 9.7) 4.8 (2.3; 11.7) 5.8 (2.8; 14.9)
Albumin (g per 100ml) 3.8 (0.3) 3.8 (0.3) 3.8 (0.3)
Hemoglobin (g per 100ml) 11.0 (1.3) 11.0 (1.3) 10.8 (1.4)
NT-pro-BNP (pg/ml) 3123 (1506; 8585) 3544 (1460; 8810) 3510 (1322; 9659)
BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; HbA1c, glycated hemoglobin A1c; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide.
Values are presented as means (s.d.) or median (interquartile range) or %.
aAbsolute change in adiponectin, as represented by the difference (adiponectinf-upadiponectinbaseline).
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Recent data showed a positive relation between adiponectin
and brain natriuretic peptides,22,26–28 as well as with left
ventricular dysfunction.26 Levels of adiponectin, in elderly
heart failure patients, were found particularly increased in
those with underlying non-ischemic origin.29 Importantly, one
study showed that carperitide infusions (atrial natriuretic
peptide) increased plasma levels of adiponectin in patients
with heart failure.30 As NT-pro-BNP also is a risk factor for
adverse outcome,31 it represents an important confounder in
the association of adiponectin with outcome. After further
adjustments for NT-pro-BNP, we were surprised by the
magnitude by which the effect estimates were lowered. In
fact, NT-pro-BNP was the only variable that largely influenced
and attenuated the association. Thus, our study suggests that
the relation of a high adiponectin level with adverse outcome
in hemodialysis patients is essentially explained by NT-pro-
BNP, potentially representative of cardiac function and
possibly fluid overload.
In line with this, the data on follow-up measurements of
adiponectin show that longitudinal increases in adiponectin
levels were related to higher risks of SD, MI, combined CVE,
and all-cause mortality. Again, the increase in adiponectin
was correlated to an increase in NT-pro-BNP, and adjust-
ments for NT-pro-BNP and its changes resulted in mean-
ingfully lower effect estimates. These data extend findings of a
previous study, suggesting an increased mortality with
increasing adiponectin,32 not taking NT-pro-BNP into
account. The proposed link of adiponectin with impaired
cardiac function may further be supported by studies in men
with angina pectoris,33 and in patients with coronary artery
disease28,34 and congestive heart failure,22,29 where elevated
circulating adiponectin levels were independent markers of
future MI, CVE, and mortality. Compared with the general
population, these patients presented with a poorer health
condition, eventually suggesting that impaired cardiac
function may have accounted for a modification of
adiponectin levels and associated risk. In future, more
research is needed to elucidate the impact of ventricular
dysfunction, hemodynamic factors, cardiac ischemia, and
volume status,35,36 as well as that of the interesting hypothesis
of an indirect stimulation of adiponectin by natriuretic
peptides through increased lipid mobilization.22
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Figure 2 |Changes in adiponectin and adverse outcomes. (a–c) Kaplan–Meier curves for the time to (a) sudden death, (b) myocardial
infarction, and (c) all-cause mortality by tertiles of the change in adiponectin from baseline. Tertile 1: patients with a decrease in adiponectin
greater than or equal to 12.8% (n¼ 400), Tertile 2: patients with stable adiponectin levels (change in adiponectin between 12.8 and
þ 12.3%; n¼ 402), Tertile 3: patients with an increase in adiponectin greater than 12.3% (n¼ 400).
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Adressing potential causal effects of adiponectin, experi-
mental data suggest the hormone to have several anti-
inflammatory properties. First, the production and action of
tumor necrosis factor-a, a key proinflammatory cytokine, is
inhibited in various cell types including cardiac and vascular
cells.37 Second, nuclear factor-kB activation in endothelial
cells and the ability to activate adenosine monophosphate-
activated protein kinase is inhibited, which resulted in the
downregulation of CRP, interleukin-8, and adhesion mole-
cule expression.5,38–43 Third, adiponectin promoted the
clearance of apoptotic cells by macrophages,44 thus counter-
acting an exacerbation of inflammation and immune
dysfunction.45 Applying this information to the clinical
situation, adiponectin may be assumed to lower CRP in
hemodialysis patients, which is a strong risk factor for
adverse outcome.46,47 In this case, adjustments for CRP in the
analyses of adiponectin with outcome, that is excluding the
potential pathway of lowering inflammation, are expected to
result in a worse association (¼ higher risk estimates for
adiponectin). Indeed, consistently higher effect estimates
were seen, suggesting that the experimentally observed anti-
inflammatory effects of adiponectin also hold true in the
clinical setting of maintenance hemodialysis.
The strengths of this prospective cohort study include the
precise and comprehensive recording of pre-specified,
centrally adjudicated outcomes, the distinction of different
components forming CVEs, the longitudinal measures of
adiponectin, the large number of patients, and the long-term
follow-up. A potential limitation may be that the adiponectin
measurements did not account for the differentiation of
isoforms, with the high-molecular-weight isoform being
suggested as the most biologically active form.48 However,
the roles of the isoforms varying in different physiopatho-
logical conditions are not yet fully established.49,50 In heart
failure populations, total adiponectin has been recommended
as the preferred measure for mortality assessments.51
In conclusion, the increased risk of CVEs seen with a high
adiponectin at baseline was mainly explained by high risks of
SD and stroke, but not of MI. Increasing adiponectin during
follow-up was associated with higher risks of adverse CV
outcomes and death, whereby the associations were mainly
explained by a confounding effect of NT-pro-BNP. Further-
more, adiponectin appears to hold anti-inflammatory
properties in hemodialysis patients. We therefore suggest
that high and increasing adiponectin in the dialysis popula-
tion largely reflects a consequence of disease circumstances,
Table 5 | Change in adiponectin from baseline (tertiles) and the risk (HR and 95% CI) of sudden death, stroke, myocardial
infarction, combined cardiovascular events, and all-cause mortality; study population n=1202
Percentage change in adiponectin from baseline
Outcome Decrease p–12.8% (n=400) Stable 12.8 to +12.3% (n=402) Increase 412.3% (n=400)
Cardiovascular events
Crude HR (95% CI) 1 1.23 (0.97–1.56) 1.33 (1.05–1.69)
Adjusteda HR (95% CI) 1 1.14 (0.87–1.50) 1.13 (0.84–1.51)
Adiponectin change as continuous variableb HRcrude 1.32 (1.02–1.71); P=0.03
HRadj 1.04 (0.75–1.44); P=0.81
Sudden death
Crude HR (95% CI) 1 1.33 (0.88–2.00) 1.51 (1.02–2.25)
Adjusteda HR (95% CI) 1 0.94 (0.57–1.57) 1.27 (0.77–2.11)
Adiponectin change as continuous variableb HRcrude 1.47 (0.95–2.27); P=0.08
HRadj 1.18 (0.66–2.11); P=0.58
Stroke
Crude HR (95% CI) 1 1.20 (0.72–2.00) 1.07 (0.63–1.80)
Adjusteda HR (95% CI) 1 1.12 (0.63–1.98) 0.87 (0.46–1.66)
Adiponectin change as continuous variableb HRcrude 1.14 (0.65–1.99); P=0.66
HRadj 0.94 (0.48–1.83); P=0.85
Myocardial infarction
Crude HR (95% CI) 1 1.40 (0.96–2.04) 1.66 (1.15–2.39)
Adjusteda HR (95% CI) 1 1.31 (0.87–1.98) 1.45 (0.94–2.23)
Adiponectin change as continuous variableb HRcrude 1.56 (1.05–2.31); P=0.03
HRadj 1.31 (0.81–2.14); P=0.27
All-cause mortality
Crude HR (95% CI) 1 1.13 (0.92–1.39) 1.29 (1.06–1.57)
Adjusteda HR (95% CI) 1 0.93 (0.73–1.19) 0.92 (0.71–1.18)
Adiponectin change as continuous variableb HRcrude 1.33 (1.07–1.66); P=0.01
HRadj 0.85 (0.64–1.13); P=0.27
BMI, body mass index; CI, confidence interval; HR, hazard ratio; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide.
aAnalyses were adjusted for age, gender, atorvastatin treatment, coronary artery disease, congestive heart failure, duration of type 2 diabetes mellitus, baseline adiponectin
levels, smoking status, systolic blood pressure, BMI, NT-pro-BNP, and C-reactive protein at baseline, longitudinal changes in BMI and longitudinal changes in NT-pro-BNP.
bThe adiponectin change (ratio adiponectinf-up/adiponectinbaseline) as continuous variable was log transformed.
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characterized by increasing NT-pro-BNP. Most likely, it is a
counter-regulatory response to worsening health while
keeping its potential to counteract inflammation.
MATERIALS AND METHODS
Study design and participants
The 4D study methodology has previously been reported in detail.52
Briefly, the 4D study was a prospective randomized controlled trial
including 1255 patients with type 2 diabetes mellitus, aged 18–80
years, and a previous duration of hemodialysis of less than 2 years.
Between March 1998 and October 2002, patients were recruited in
178 participating dialysis centers in Germany. After a period of 4
weeks, patients were randomly assigned to double-blind treatment
with either 20mg atorvastatin (n¼ 619) or placebo (n¼ 636) once
daily. Study visits took place three times before randomization
(visits 1–3), at randomization (visit 4), and at 4 weeks (visit 5) and
every 6 months (visit 6 and so on) after randomization until the
date of death, censoring, or end of the study in February 2004. The
primary end point of the 4D study was defined as a composite of
death from cardiac causes, stroke, and MI, whichever occurred first.
Death from any cause, SD, stroke, and MI were secondary study end
points. 4D study end points were centrally adjudicated by three
members of the end point committee blinded to study treatment
and according to pre-defined criteria.15
For the present analysis, SD, stroke, MI, the combined CVend point
(CVE: cardiac death, stroke, and MI), and all-cause death were all
chosen to be separate outcome measures and were based on the
primary judgement of the end point committee during the 4D study.
Data collection
Information on age, gender, and smoking status was obtained
through patient interviews. Smoking status was classified as never,
former, or current. Comorbidities, including the presence of
coronary artery disease and congestive heart failure, as well as the
duration of diabetes mellitus and dialysis treatment were reported
by the patients’ nephrologists. Blood pressure was measured in the
sitting position. BMI was calculated as weight (kg) divided by height
(m) squared. All laboratory measurements of the 4D study were
performed centrally at the Department of Clinical Chemistry,
University of Freiburg, Germany. Adiponectin was measured in
blood samples taken at study visit 3 (1 week before randomization)
and visit 6 (6 months after randomization). If there was no sample
available at visit 6 (n¼ 20), a sample taken at the following study
visit was chosen (visit 7: n¼ 19; visit 11: n¼ 1). Measurements of
adiponectin were performed by enzyme-linked immunosorbent
assay (Human Adiponectin ELISA; BioVendor GmbH, Heidelberg,
Germany). Interassay coefficients of variance were o5%. All blood
samples were taken before the start of dialysis sessions and
administration of drugs.
Statistical analysis
The study population was divided into four groups, according to
quartiles of adiponectin levels at baseline. Continuous variables were
expressed as mean with s.d. or median with interquartile range as
appropriate, and categorical variables were expressed as percentages.
In general, associations of adiponectin with outcome were
assessed by absolute (incidence) rates to reach the pre-specified end
points, and by relative risks derived from Cox regression analyses,
that is HRs and corresponding 95% confidence intervals. After
identifying confounders according to epidemiologic criteria,53,54
multivariate Cox regression analyses were performed adjusting for
age, gender, atorvastatin treatment, coronary artery disease,
congestive heart failure, duration of type 2 diabetes mellitus,
smoking status, and systolic blood pressure.
In detail, the following analyses were performed. First, the
association of baseline adiponectin with the pre-defined outcome
measures of SD, stroke, MI, CVE, and all-cause mortality was
analyzed, both as a continuous variable (logarithmically trans-
formed because values were not normally distributed) and as a
categorical variable (baseline adiponectin quartiles).
Second, we investigated the role of BMI, NT-pro-BNP, and CRP
in the association of adiponectin with outcome. We therefore
determined the correlation of adiponectin with BMI, NT-pro-BNP,
and CRP, and adjusted our analyses on adiponectin and outcome
additionally and stepwise for these variables. Furthermore, trigly-
cerides and high-density lipoprotein cholesterol levels were similarly
considered in additional analyses.
Third, to investigate the longitudinal variations in adiponectin,
we calculated the relative change of adiponectin from baseline to the
next available follow-up measurement, predominantly taken at 6
months (change in adiponectin¼ ratio adiponectinf-up/adiponec-
tinbaseline). Patients were divided into tertiles according to the
relative change in adiponectin. The association between the relative
change of adiponectin and outcome was then assessed as a
continuous variable (log transformed), and as a categorical variable
using the tertiles. The observation period contributing for the Cox
regression analyses thereby started from the day of the respective
follow-up measurement used to assess the change in adiponectin.
Adjustments were made for baseline variables and additionally for
longitudinal changes in BMI and NT-pro-BNP, its relations with
adiponectin before being evaluated in correlation analyses.
To account for potential interaction by gender, we performed
further analyses in strata of male and female patients.
In general, to compare adiponectin between the atorvastatin and
placebo groups, the Wilcoxon rank-sum test was used, whereas the
Wilcoxon signed-rank test was applied to compare baseline with
post-baseline adiponectin levels. All P-values are reported two-sided.
Analyses were performed using SPSS version 16.0.
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